FORM PTO 1449 (modified)	Atty. Docket No. X-15876	Serial No 10/526,960	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Maria-Jesus Blanco-Pillado		
	PCT Application Date: September 17, 2003	Group Art Unit 1624	
	US Nat'l Entry Date: March 3, 2005		

U.S. PA	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AC	US 4,191,771	March 4, 1980	Zimmerman	
	AD	US 4,891,379	January 2, 1990	Zimmerman, et al.	
	AE	US 6,140,352	October 31, 2000	Crowell, et al.	

Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -  Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т <sup>6</sup>
	BI	EP 1 072 592	31 January 2001	Pfizer, Inc.		
	BJ	WO 02/078693	10 October 2002	Eli Lilly and Company		
Examiner Initials*	Cite No. 1	Include name of the author	erial, symposium, catalog,	), title of the article (when etc.), date, page(s), volur	appropriate), title of the item ne-issue number(s) publisher,	T <sup>6</sup>
	CA	city and/or country where published.  Wentland, et al., "8-Carboxamidocyclazocine Analogues: Redefining the Structure- Activity Relationships of 2,6-Methano-3-Benzazocines," <u>Bioorganic &amp; Medicinal</u> Chemistry Letters, Vol. 11, pps. 623-626 (2001)				
	0.1	Activity Relationship		enzazocines," Bioor		
	СВ	Activity Relationship Chemistry Letters, Vo Wentland, et al., "3-C	ol. 11, pgs. 623-626 ( arboxamido Analogu Binding Properties,"	enzazocines," <u>Bioor</u> 2001) les of Morphine and		

Examiner	/Jeffrev Murray/	Date Considered	12/26/2007
Signature			(11111011100)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unappe citation designation member (optional). <sup>2</sup> See Kinds Codes of USPTO Potent Documents at www.uupto.pov or MPEP 901.04. <sup>3</sup>Enter Office that usued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of Securing by the appropriate symbols in makinest on the document under WIPO Standard ST, 16 if possible. Appleant is to place in doct much for Highligh happings Trenthions in situation.

Agreements on the mixed of time syn